1. Introduction {#sec1-ijerph-17-03738}
===============

Depression is one of the major leading causes of disability worldwide, affecting approximately 400 million people \[[@B1-ijerph-17-03738]\], with 9% of men and 17% of women experiencing depressive symptoms at least once in their life. Mainly due to social prejudices, depression continues to be frequently under-diagnosed and inadequately treated \[[@B2-ijerph-17-03738]\]. Depression can have several negative consequences, being characterized by sad mood and/or loss of interest, affecting thoughts, feelings, behaviors, physical health and impairing social and occupational functioning \[[@B3-ijerph-17-03738],[@B4-ijerph-17-03738]\]. Furthermore, over 80% of depressed patients have more than one depressive episode during their lifespan \[[@B5-ijerph-17-03738],[@B6-ijerph-17-03738]\]. In this context, innovative and effective preventive and therapeutic strategies are required.

Current studies are focusing on the important role played by lifestyles and in particular physical activity (PA), in both preventing and treating depression \[[@B7-ijerph-17-03738]\]. Several biological mechanisms are potentially involved in the association between PA and depression, such as the noradrenergic and serotoninergic effects of physical activity \[[@B8-ijerph-17-03738]\], the hypothalamic-pituitary-adrenal axis regulation \[[@B9-ijerph-17-03738]\], the production of neurotrophic factor \[[@B10-ijerph-17-03738]\], and lastly the improvement in vascular function and oxygenation \[[@B11-ijerph-17-03738],[@B12-ijerph-17-03738]\]. However, despite the high number of potential explanations, evidence is not concordant in proven positive association between PA and depression, for both prevention and treatment. One of the main reasons behind these contrasting results could be the different methods used to measure physical activity.

Two recent meta-analyses focusing on prevalent depression and incident depression found an inverse association between prevalent depression and PA \[[@B13-ijerph-17-03738]\], while this association was not significant when incident depression has been considered \[[@B14-ijerph-17-03738]\]. However, the study conducted by Schuch et al. retrieved only one paper using the objectively measured PA \[[@B13-ijerph-17-03738]\]. The meta-analysis conducted by Krogh et al. included trials that prescribed different types of exercise sessions without objectively measuring PA \[[@B14-ijerph-17-03738]\]. On the other hand, growing evidence is focusing on objectively measured physical activity, using for instance accelerometer and pedometer, showing how objectively measured PA is more precise than self-reported one. This was particularly true in estimating duration, total amount and intensity \[[@B15-ijerph-17-03738]\].

We performed a systematic review with meta-analysis of the evidence from the literature to assess the relation between physical activity objectively measured and incident and prevalent depression.

2. Materials and Methods {#sec2-ijerph-17-03738}
========================

We conducted this systematic review according to the methods recommended by the Cochrane Collaboration \[[@B16-ijerph-17-03738]\] and to the Meta-analysis Of Observational Studies in Epidemiology (MOOSE) guidelines \[[@B17-ijerph-17-03738]\] and documented the process and results in accordance with the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guidelines \[[@B18-ijerph-17-03738]\]. The review protocol has been registered on PROSPERO \[[@B19-ijerph-17-03738]\], the International Prospective Register of Systematic Reviews funded by the National Institute of Health Research (<https://www.crd.york.ac.uk/prospero/>).

2.1. Information Sources and Search Strategy {#sec2dot1-ijerph-17-03738}
--------------------------------------------

Studies were identified searching through the electronic databases PubMed/MEDLINE, Embase, Scopus, Web of Science (WoS), PsycINFO and the Cochrane Library. We combined the search strategy of free text terms and exploded MESH headings for the topics of depression, physical activity, objective measurements, and type of study. The strategy was firstly developed in PubMed/MEDLINE and then adapted for use in the other databases ([Supplementary Table S1](#app1-ijerph-17-03738){ref-type="app"}). Studies conducted on human subjects and published in English through 31 August 2019 were included.

2.2. Inclusion and Exclusion Criteria {#sec2dot2-ijerph-17-03738}
-------------------------------------

We considered studies that investigated the relation between physical activity objectively measured and depression, both as a continuous and as a binary variable. Adult participants of both sexes were considered. As done before \[[@B20-ijerph-17-03738],[@B21-ijerph-17-03738]\], both population-based and hospital-based studies were included. Among hospital-based studies, inpatients, day-hospital, and outpatient subjects were included while emergency care records were excluded as considered non-representative. All experimental and observational study designs were included apart from case reports. Narrative and systematic reviews, letters to the editor and book chapters were excluded. [Table 1](#ijerph-17-03738-t001){ref-type="table"} shows a detailed description of inclusion/exclusion criteria according to the Population, Exposure, Outcomes and Study design (PEOS) \[[@B22-ijerph-17-03738]\], adjusted for observational studies extended with time and language filters, as recommended by the Cochrane Collaboration \[[@B16-ijerph-17-03738]\].

2.3. Study Selection and Data Extraction {#sec2dot3-ijerph-17-03738}
----------------------------------------

Identified studies were independently reviewed for eligibility by two couples of authors (VG, LB, MM, SC) in a two-step process: a first screening was performed based on title and abstract, while full texts were retrieved for the second screening. At both stages disagreements by reviewers were resolved by consensus. Data were independently extracted by three authors (LB, MM, SC) and supervised by a senior author (VG) using an ad-hoc developed data extraction spreadsheet. The data extraction spreadsheet was piloted on 10 randomly selected papers and modified accordingly. As done before \[[@B23-ijerph-17-03738],[@B24-ijerph-17-03738],[@B25-ijerph-17-03738]\], both qualitative and quantitative data was extracted from the original studies. Qualitative data recorded included the following items: name of first author and year of publication, country where the study was conducted and period during which the study was performed, device used to measure PA and tool used for depression diagnosis. Moreover, characteristics of the subjects were recorded (e.g., age, gender, comorbidities). Quantitative data extracted includes: sample size, number of participants lost (attrition), duration of PA measurement, distribution of depressed participants in the sample, level of PA performed and the results estimating the association between PA objectively measured and depression.

2.4. Quality Evaluation {#sec2dot4-ijerph-17-03738}
-----------------------

The quality evaluation of the included publications were independently assessed by two authors using the New-Ottawa Scale \[[@B26-ijerph-17-03738]\] for observational studies and Cochrane Collaboration tool for trials \[[@B27-ijerph-17-03738]\].

2.5. Meta-Analysis {#sec2dot5-ijerph-17-03738}
------------------

We pooled individual studies data using ProMeta3^®^ (Internovi, Milano, Italy) software. Due to heterogeneity, a random effects meta-analysis was employed. In order to reduce the heterogeneity, two sensitivity analyses were conducted, considering the following items: (i) study design, (ii) participants' comorbidities. Moreover, a subgroup analysis by gender was conducted in order to estimate potential different effects among the two groups. We assessed publication bias with the visual inspection of a funnel plot \[[@B27-ijerph-17-03738]\] and the Begg \[[@B28-ijerph-17-03738]\] and Egger \[[@B29-ijerph-17-03738]\] tests.

3. Results {#sec3-ijerph-17-03738}
==========

3.1. Literature Search {#sec3dot1-ijerph-17-03738}
----------------------

A total of 4279 articles were retrieved. After a preliminary screening 670 articles were excluded because of duplicates, 409 not original papers (reviews, letters to the editor, editorials, protocols, etc.), and 2796 covering a different topic. After title and abstract screening, a total of 192 full-text articles were consulted, while at the end of the screening process only 41 were included in the systematic review \[[@B30-ijerph-17-03738],[@B31-ijerph-17-03738],[@B32-ijerph-17-03738],[@B33-ijerph-17-03738],[@B34-ijerph-17-03738],[@B35-ijerph-17-03738],[@B36-ijerph-17-03738],[@B37-ijerph-17-03738],[@B38-ijerph-17-03738],[@B39-ijerph-17-03738],[@B40-ijerph-17-03738],[@B41-ijerph-17-03738],[@B42-ijerph-17-03738],[@B43-ijerph-17-03738],[@B44-ijerph-17-03738],[@B45-ijerph-17-03738],[@B46-ijerph-17-03738],[@B47-ijerph-17-03738],[@B48-ijerph-17-03738],[@B49-ijerph-17-03738],[@B50-ijerph-17-03738],[@B51-ijerph-17-03738],[@B52-ijerph-17-03738],[@B53-ijerph-17-03738],[@B54-ijerph-17-03738],[@B55-ijerph-17-03738],[@B56-ijerph-17-03738],[@B57-ijerph-17-03738],[@B58-ijerph-17-03738],[@B59-ijerph-17-03738],[@B60-ijerph-17-03738],[@B61-ijerph-17-03738],[@B62-ijerph-17-03738],[@B63-ijerph-17-03738],[@B64-ijerph-17-03738],[@B65-ijerph-17-03738],[@B66-ijerph-17-03738],[@B67-ijerph-17-03738],[@B68-ijerph-17-03738],[@B69-ijerph-17-03738],[@B70-ijerph-17-03738]\]. As it was not possible to extrapolate data from one study, it was not included in the quantitative evaluation \[[@B67-ijerph-17-03738]\]. [Figure 1](#ijerph-17-03738-f001){ref-type="fig"} shows the selection process. Two studies reported separate data for men and women \[[@B49-ijerph-17-03738],[@B54-ijerph-17-03738]\] and for this reason they were considered separately, resulting in 42 datasets being included in the meta-analysis.

The characteristics of the included studies are reported in [Table 2](#ijerph-17-03738-t002){ref-type="table"}. The majority of the studies were conducted in Europe (*n* = 18, 43%) and North America (*n* = 12, 29%). The first study assessing objectively measure PA and depression was published in 2004 \[[@B68-ijerph-17-03738]\]. The smallest sample size included in a study was of 23 participants \[[@B70-ijerph-17-03738]\], whereas the largest sample size was of 16,415 participants \[[@B62-ijerph-17-03738]\]. Twenty-six of the 42 datasets were cross-sectional (62%), eight trials (19%), six cohort studies (14%), and one case-control study (2%). The quality assessment of trials is reported in [Supplementary Table S2](#app1-ijerph-17-03738){ref-type="app"}. Thirty-two datasets (76%) used an accelerometer as the measurement device, while nine datasets (21%) used a pedometer. In almost all studies participants were asked to wear the device for 7 days, and even in cohort studies PA was measured only at baseline. With regard to depression, heterogeneous tools were used to make diagnosis, such as the Hospital Anxiety and Depression Scales (HADS), the Patient Health Questionnaire-9 (PHQ-9), the Beck Depression Inventory (BDI-II) and the Center for Epidemiologic Studies Depression Scale (CESD). Most of the time HADS was used (*n* = 11), followed by PHQ-9 questionnaire (*n* = 9); however almost all studies used a validated tool. At the same time, the results were expressed using different measures, as for instance Odd Ratio (OR), Relative Risk (RR), β coefficient (β) and Spearman's Rho (r).

3.2. Results of Meta-Analysis {#sec3dot2-ijerph-17-03738}
-----------------------------

The pooled ES was −1.16 \[(95% CI = −1.41; −0.91), *p*-value \< 0.001\] based on 37,408 participants ([Figure 2](#ijerph-17-03738-f002){ref-type="fig"}a), with high statistical heterogeneity (Chi^2^ = 15,090.18, df = 41, I^2^ = 99.73, *p*-value \< 0.001). A potential publication bias was found by the visual assessment of the funnel plot and confirmed by the Egger's linear regression test (Intercept −5.85, t = −1.91, *p*-value = 0.063). However, the ES estimated did not change after the trim and fill method ([Figure 2](#ijerph-17-03738-f002){ref-type="fig"}b).

3.3. Sensitivity Analysis by Participants' Comorbidities {#sec3dot3-ijerph-17-03738}
--------------------------------------------------------

The sub-group analysis considering only the general population (without diseases), included 21 datasets, and the pooled ES was −1.32 \[(95% CI = −1.67; −0.97), *p*-value \< 0.001\] based on 33,812 subjects. High statistical heterogeneity was found (Chi^2^ = 14,715.47, df = 20, I^2^ = 99.86, *p*-value \< 0.001). However, no publication bias was found by the visual assessment of the funnel plot and confirmed by the Egger's linear regression test (Intercept −9.46, t = −1.50, *p*-value = 0.150). The sub-group analysis considering patients with chronic obstructive pulmonary disease (COPD), included 6 datasets, and the pooled ES was −1.08 \[(95% CI = −1.91; −0.24), *p*-value = 0.012\] based on 683 subjects. High statistical heterogeneity was found (Chi^2^ = 33.35, df = 5, I^2^ = 85.01, *p*-value \< 0.001). However, no publication bias was found by the visual assessment of the funnel plot and confirmed by the Egger's linear regression test (Intercept −4.12, t = −2.06, *p*-value = 0.109). The sub-group analysis considering obese participants, included 5 datasets, and the pooled ES was −0.35 \[(95% CI = −0.80; 0.10), *p*-value = 0.128\] based on 1354 participants. High statistical heterogeneity was found (Chi2 = 22.86, df = 4, I^2^ = 82.50, *p*-value \< 0.001). However, no publication bias was found by the visual assessment of the funnel plot and confirmed by the Egger's linear regression test (Intercept −1.86, t = −1.65, *p*-value = 0.197). The sub-group analysis considering participants with (any type of) cancer, included 5 datasets, and the pooled ES was −1.79 \[(95% CI = −3.35; −0.22), *p*-value = 0.025\] based on 955 participants. High statistical heterogeneity was found (Chi^2^= 112.21, df = 4, I^2^ = 96.44, *p*-value \< 0.001). However, no publication bias was found by the visual assessment of the funnel plot and confirmed by the Egger's linear regression test (Intercept 1.27, t = 0.16, *p*-value = 0.885).

3.4. Sensitivity Analysis by Study Design {#sec3dot4-ijerph-17-03738}
-----------------------------------------

The sub-group analysis considering only observational studies (cross-sectional, cohort and case-control studies), included 34 datasets, and the pooled ES was −0.99 \[(95% CI = −1.26; −0.72), *p*-value \< 0.001\] based on 34,764 participants. High statistical heterogeneity was found (Chi^2^ = 14,809.58, df = 33, I^2^ = 99.78, *p*-value \< 0.001). However, no publication bias was found by the visual assessment of the funnel plot and confirmed by the Egger's linear regression test (Intercept −6.13, t = −1.61, *p*-value = 0.118). The sub-group analysis considering only cross-sectional analysis, included 27 datasets, and the pooled ES was −0.23 \[(95% CI = −0.30; −0.16), *p*-value \< 0.001\] based on 17,191 participants. A high statistical heterogeneity was found (Chi^2^ = 240.33, df = 26, I^2^ = 89.18, *p*-value \< 0.001). A publication bias was found by the visual assessment of the funnel plot and confirmed by the Egger's linear regression test (Intercept −2.25, t = −4.89, *p*-value \< 0.001). The sub-group analysis considering only cohort datasets, included 6 datasets, and the pooled ES was −2.61 \[(95% CI = −7.41; 2.21), *p*-value \< 0.289\] based on 17,515 participants. High statistical heterogeneity was found (Chi^2^ = 10105.57, df = 5, I^2^ = 99.95, *p*-value \< 0.001). However, no publication bias was found by the visual assessment of the funnel plot and confirmed by the Egger's linear regression test (Intercept −4.06, t = −0.12, *p*-value = 0.909). The sub-group analysis considering only interventional studies (trials), included 8 datasets, and the pooled ES was −2.63 \[(95% CI = −4.06; −1.20), *p*-value \< 0.001\] based on 2644 participants. High statistical heterogeneity was found (Chi^2^ = 224.80, df = 7, I^2^ = 96.89, *p*-value \< 0.001). Potential publication bias was found by the visual assessment of the funnel plot and confirmed by the Egger's linear regression test (Intercept −5.12, t = −2.56, *p*-value = 0.043).

3.5. Subgroup Analysis by Gender {#sec3dot5-ijerph-17-03738}
--------------------------------

Considering The sub-group analysis considering only women, included seven datasets, and the pooled ES was −1.91 \[(95% CI = −2.77; −1.04), *p*-value \< 0.001\] based on 1415 participants. High statistical heterogeneity was found (Chi^2^ = 217.37, df = 6, I^2^ = 97.24, *p*-value \< 0.001). Potential publication bias was found by the visual assessment of the funnel plot and confirmed by the Egger's linear regression test (Intercept −5.29, t = −3.82, *p*-value = 0.012). The sub-group analysis considering only men, included three datasets, and the pooled ES was −0.11 \[(95% CI = −0.38; 0.16), *p*-value = 0.430\] based on 928 participants. A high statistical heterogeneity was found (Chi^2^ = 240.33, df = 26, I^2^ = 89.18, *p*-value \< 0.001). However, no publication bias was found by the visual assessment of the funnel plot and confirmed by the Egger's linear regression test (Intercept −1.20, t = −0.99, *p*-value = 0.503).

4. Discussion {#sec4-ijerph-17-03738}
=============

The current systematic review with meta-analysis---which included 43 studies in qualitative evaluation and 42 studies in the quantitative analysis---provided data on the association between objectively measured PA and the risk of depression. Since some studies expressed data separated for gender, a total of 42 datasets have been considered. The pooled ES based on 37,408 subjects indicated a significantly protective effect of PA on depression \[−1.16 (95% CI = −1.41; −0.91), *p*-value \< 0.001\] while, in the subgroup analysis including only cross-sectional datasets, the risk of prevalent depression was estimated on 17,191 participants and the ES was −0.23 \[(95% CI = −0.30; −0.16)\]. In subgroup analysis including only longitudinal datasets, the risk of incident depression, estimated on 17,515 participants, was lower −2.61 \[(95% CI = −7.41; 2.21).

With the purpose of deeply understanding the strength of the association between objectively measured PA and depression, a sub-group analysis by participants' comorbidity has been conducted. When studies assessing the association among participants with comorbidities were considered, the ES were not statistically significant (apart for COPD participants). However, prescription of adapted PA among participants affected by co-morbidities should be considered \[[@B71-ijerph-17-03738]\]. To the contrary, when only studies with general population (otherwise healthy people) were considered, the pooled ES was statistically significant, indicating an inverse association between PA objectively measured and depression (more PA was associated with lower risk of depression). A subgroup analysis by gender was conducted as well, showing a protective effect of PA only for women. However, this result should be considered carefully, since only three studies assessed PA and depression only in men, reducing the sample size.

These results are extremely important considering that depression is one of the leading causes of disabilities worldwide \[[@B1-ijerph-17-03738]\]. In the last fifty years a great concern was casted on physical health of depressed individuals. This could be due because physical exercise seems to improve several biomarkers implicated in depression (e.g., impaired neuroplasticity, autonomic and immune imbalances) \[[@B9-ijerph-17-03738]\]. In in-vivo models, physical activity showed a serotoninergic effect as some antidepressant medications \[[@B8-ijerph-17-03738]\]. Moreover, PA has demonstrated an effect on inflammatory processes, through the hypothalamic-pituitary-adrenal axis regulation involved in the development of depression \[[@B9-ijerph-17-03738]\]. Additionally, higher levels of brain derived neurotrophic factor have been found after physical exercise \[[@B10-ijerph-17-03738]\]. Lastly, the level of PA directly affects the upper limit of oxygen uptake which depends on the capacity of the cardiorespiratory system to transport oxygen to the organs, including the brain. A lower oxygenation of the brain may result in a chronic cerebral ischemia and, if the affected areas are involved in a mood regulation, this may increase the risk of depression \[[@B12-ijerph-17-03738]\].

In the last decades, several studies have shown that a healthy lifestyle, in particular the intensity and length of physical activity \[[@B72-ijerph-17-03738],[@B73-ijerph-17-03738]\], are important in the prevention and treatment of depression \[[@B7-ijerph-17-03738]\]. In our analysis we could not assess the relation between severity of depression and intensity of PA, as in most of the primary studies included, severity of depression was not reported and PA intensity was expressed using different methods. The results from our review confirm the beneficial effect of PA on depression, especially for participants without comorbidities. In this regard, health education campaigns aimed to promote PA should be fostered \[[@B74-ijerph-17-03738],[@B75-ijerph-17-03738],[@B76-ijerph-17-03738]\], especially because approximately 40% of the adult population worldwide is insufficiently physical active \[[@B77-ijerph-17-03738]\]. However, in order to better interpret our results, another important aspect should be considered: indeed, even if several sub-group analyses have been conducted, the value of heterogeneity remained stably high. Although a sensitivity analysis including only datasets with otherwise healthy people has been conducted, the I^2^ remained extremely high. However, a I^2^ value higher than 90% means that heterogeneity is directly due to heterogeneity among studies, instead of sampling error \[[@B78-ijerph-17-03738]\]. Moreover, primary papers expressed the level of PA using different types of unit of measures and also the results were reported using different modalities. Even if the pooled ES has been estimated by log OR, allowing comparability, this underlying heterogeneity might have affected the assessment of the I^2^ \[[@B79-ijerph-17-03738]\]. Another potential explanation of heterogeneity could be the different type of duration of measurement, the device used and the questionnaire adopted to diagnose depression. Furthermore, a variety of confounding variables were selected in original studies and, in order to control the results, we pooled the models with the highest level of adjustment.

Limitantions and Strengths
--------------------------

The main limitation of this systematic review is the high I^2^ value that might reduce the generalizability of our results. Most studies are observational and based on cross-sectional analysis. Nevertheless, we performed sensitivity analyses only including trials and longitudinal studies, increasing the robustness of our results. Due to the high heterogeneity in reporting the level of PA performed by participants in original studies, it was not possible to identify a recommended level of PA. The inability to estimate an association between severity of depression and PA is another important limitation. The main strengths of this review are being systematic in nature and its comprehensive way to include the entire scientific evidence published so far on the main medical-scientific databases. Furthermore, the pooled ES was significantly large, based on 37,408 participants, and sub-group analyses have been conducted based on participants' comorbidity and study design. In the primary studies, diagnosis of depression was consistently based on the DSM criteria and was established by trained investigators using validated assessment scales mainly with interrater reliability.

5. Conclusions {#sec5-ijerph-17-03738}
==============

To conclude, the results of this systematic review and meta-analysis clearly show a statistically significant protective effect of objectively measured PA on prevalent and incident depression. An increased PA is associated with lower risk of depression. The advantages of our study are several. Firstly, this study offers a systematic overview of previous studies assessing objectively measured PA and depression. Secondly, this study highlights the usefulness of objectively measured PA compared to self-reported one. Objectively measured PA is not only more precise in estimating duration, total amount, and intensity of PA, but indirectly it can also better strengths the association with some diseases, as depression. Thirdly, this study shows the importance to promote physical activity forasmuch it can help to reduce the high burden of depression in our society. Lastly, our findings are relevant for both policy makers and clinicians as physical activity is one of the cheapest, non-pharmacological treatment that might be prescribed to the general population with potentially major public health impact. Physical activity is important across ages and should be integrated into daily life.

The following are available online at <https://www.mdpi.com/1660-4601/17/10/3738/s1>, F, Table S1: Search strategy in PubMed/MEDLINE, Table S2: Assessment of risk of bias for trials, using The Cochrane Collaboration's.
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ijerph-17-03738-t001_Table 1

###### 

Detailed description of inclusion/exclusion criteria according to a Population, Exposure, Outcomes and Study design (PEOS).

  -----------------------------------------------------------------------------------------------------------------------------------------------
  Search Strategy      Details
  -------------------- --------------------------------------------------------------------------------------------------------------------------
  Inclusion criteria   P: adults (men and women)\
                       E: physical activity objectively measured\
                       O: Depressive disorder\
                       S: Trials, cohort studies, case-control, cross-sectional

  Exclusion criteria   P: people \< 18 years old\
                       E: physical activity not objectively measured (self-reported)\
                       O: other psychological disorders\
                       S: not original papers (opinion paper, review article, commentary, letter, protocols, article without quantitative data)

  Language filter      English

  Time filter          No filter (from inception)

  Database             PubMed/Medline; EMBASE, Web of Science; Scopus, PsycoInfo, Cochrane
  -----------------------------------------------------------------------------------------------------------------------------------------------

ijerph-17-03738-t002_Table 2

###### 

Descriptive characteristics of the included studies stratified by study design and listed in alphabetical order.

  ---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Author\                       Country                                       Characteristics                                                          Study Period                Age and Gender                    Sample Size and Gender       Depressed Subjects           Attrition +       Device Used                                                                                  Duration of Measurement                              Tool Used for Depression Diagnosis                           PA                                                         Results                                                    QS
  Year \[Reference\]                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  
  ----------------------------- --------------------------------------------- ------------------------------------------------------------------------ --------------------------- --------------------------------- ---------------------------- ---------------------------- ----------------- -------------------------------------------------------------------------------------------- ---------------------------------------------------- ------------------------------------------------------------ ---------------------------------------------------------- ---------------------------------------------------------- ---------------
  **Cross-sectional studies**                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                         

  Al-Eisa, 2014\                Saudi Arabia                                  Female students                                                          2014                        Mean: 20.9 ± 1.4 y, F             76                           52%                          29                Pedometer                                                                                    3 weeks                                              BDI-II                                                       PA = 8715 steps/day                                        R = −0.78\                                                 4
  \[[@B31-ijerph-17-03738]\]                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                               *p* ≤ 0.01;                                                

  Alosco, 2012\                 USA                                           Persons with heart failure                                               *n*.a.                      Mean: 68.81 ± 8.8 y, M, F         96\                          *n*.a.                       27                GT1M+ accelerometer (ActiGraph, Pensacola, Florida)                                          7 days at baseline, 3 months, 12 months              BDI-II                                                       MVPA = 3.24 ± 9.0 min/day                                  β = −64.35\                                                6
  \[[@B32-ijerph-17-03738]\]                                                                                                                                                                                         (M = 63, 5%, F = 36, 5%)                                                                                                                                                                                                                                                                                                                              *p* \< 0.05\                                               
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           t = −2.32                                                  

  Altenburg, 2013\              The Netherlands                               Patients with stable chronic obstructive pulmonary disease (COPD)        *n*.a.                      Mean: 62 (54--69) y\              155 (M = 102, F = 53)        *n*.a.                       0                 Yamax-Digiwalker pedometer (SW-200)                                                          2 weeks                                              HADS                                                         PA = 4206 (2387--6284) steps/day                           R = −0.191\                                                4
  \[[@B33-ijerph-17-03738]\]                                                                                                                                                       M, F                                                                                                                                                                                                                                                                                                                                                                                    *p* \< 0.05                                                

  Arrieta, 2018\                Spain                                         Partecipants from nursing home                                           October 2016--June 2017     84.9 ± 6.9 years                  114 (81 F, 33 M)             25% (at risk of depression   0                 Actigraph GT3X model                                                                         7 days                                               GDS                                                          MVPA = 0.9 ± 1.2 min/day                                   β = 1.142\                                                 7
  \[[@B34-ijerph-17-03738]\]                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                               *p* = 0.028                                                

  Bade, 2018\                   USA                                           Lung Cancer Patients                                                     2014--2015                  Mean: 66 ± 7.75(SD) y (51--80)\   30\                          *n*.a.                       43                Accelerometer (Fitbit Zip)                                                                   7 days                                               PHQ-9                                                        PA = 4877 ± 305                                            R = −0.40                                                  5
  \[[@B35-ijerph-17-03738]\]                                                                                                                                                       M, F                              (M = 20, F = 10)                                                                                                                                                                                                                                                                                                                                                                                                 

  Barriga, 2014\                Portugal                                      COPD patients                                                            *n*.a.                      Mean: 67 ± 9.6 y, M               55 (sex *n*.s.)              *n*.a.                       0                 Pedometer                                                                                    Number of steps per day, on three consecutive days   HADS                                                         PA = 4972.4 ± 2242.3                                       R = −0.424\                                                3
  \[[@B36-ijerph-17-03738]\]                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                               *p* \< 0.01                                                

  Di Marco, 2014\               Italy                                         COPD patients                                                            *n*.a.                      Mean: 71 ± 6 y\                   70\                          19 (47% F)                   0                 Accelerometer (SenseWear Pro Armband, BodyMedia)                                             5 days                                               HADS                                                         No Depression PA = 6950 ± 2431 Depresed PA = 5055 ± 2576   β = 0.106\                                                 6
  \[[@B37-ijerph-17-03738]\]                                                                                                                                                       M, F                              (M = 52, F = 18);\                                                                                                                                                                                                                                                                                                                                    *p* = 0.84                                                 
                                                                                                                                                                                                                     No Depression = 51 (18% F)                                                                                                                                                                                                                                                                                                                                                                                       

  Dillon, 2017\                 Ireland                                       Patients in the 50--69 year age group.                                   2011                        Mean: 59.6 ± 5.5 y\               397\                         18.2%                        78                Accelerometer (ActivInsights Ltd.)                                                           7 days                                               CESD-20                                                      Mean Light PA No Depression = 103 min/day\                 β = −0.34\                                                 7
  \[[@B38-ijerph-17-03738]\]                                                                                                                                                       M, F                              (M = 182, F = 214)                                                                                                                                                                                                                                                                         Depressed = 105 min/day                                    (95% CI = −0.64 to −0.04)                                  

  Drieling, 2014\               USA                                           Obese latino immigrants                                                  July 2009--September 2010   *n*.a.                            207 (48 M, 159 F)            36.7%                        0                 Pedometer                                                                                    7 days                                               CESD                                                         6.3 ± 3.1 steps/day in thousands                           β = −0.02\                                                 6
  \[[@B39-ijerph-17-03738]\]                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                               SE 0.01\                                                   
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           *p* = 0.03                                                 

  Elbelt, 2015\                 Germany                                       High grade obesity                                                       2008--2010                  Mean: 42 ± 12 y                   50 (10 M, 40 F)              36%                          0                 Accelerometer                                                                                3 days                                               PHQ-9                                                        No depressed: 6023 ± 2459 steps/day\                       r = 0.023                                                  7
  \[[@B41-ijerph-17-03738]\]                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    Depressed: 6532 ± 3085 steps/day                                                                                      

  Fenton, 2017\                 England                                       Rheumatoid Arthritis patients                                            *n*.a.                      Mean: 54.92 ± 12.39 y             61 (F = 67.2%)               *n*.a.                       36                Actigraph GT3X+, accelerometer (Pensacola, FL)                                               7 days                                               HADS                                                         LPA = 269.35 ± 69.35 min/day                               β = −0.30\                                                 10
  \[[@B42-ijerph-17-03738]\]                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                               *p* \< 0.05                                                

  Gaskin, 2016\                 Australia                                     Prostate cancer survivors                                                *n*.a.                      65.6 ± 8.5 y                      98 (M)                       *n*.a.                       *n*.a.            ActiGraph GT1 M (Pensacola, FL)                                                              7 days                                               CESD                                                         MVPA = 38 min/day                                          β = ·0.00\                                                 10
  \[[@B44-ijerph-17-03738]\]                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                               *p* = 0.97                                                 

  Howie, 2018\                  Australia                                     Subsample of the 22th follow-up measurement of the Raine cohort Study.   2011                        *n*.a.                            475 (256 F, 219 M)           1.3%                         299               Actigraph GT3X+, accelerometer Pensacola, FL                                                 7 days                                               DASS-21                                                      MVPA\                                                      F: RR = 0.99 (95% CI = 0.98--1.00), *p* = 0.078\           10
  \[[@B49-ijerph-17-03738]\]                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    F = 27 min/day\                                            M: RR= 1.01 (95% CI = 0.99--1.02), *p* = 0.300             
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                M = 34.1 min/day                                                                                                      

  Huong, 2013\                  USA                                           COPD patients                                                            *n*.a.                      Mean: 66.5 ± 8.8 y\               148\                         29%                          0                 Accelerometer Stepwatch 3 Activity Monitor (OrthoCare Innovations LLC)                       7 days                                               HADS                                                         Mean = 6.079 ± 3718                                        β = −0.19\                                                 7
  \[[@B58-ijerph-17-03738]\]                                                                                                                                                       M, F                              (M = 115, F = 33)                                                                                                                                                                                                                                                                                                                                     *p* = 0.02)                                                

  Jung, 2018\                   Japan                                         Community-dwelling older Japanese adults.                                2013                        Mean: \>75 y\                     3054\                        598                          2.203             Accelerometer (GT40-020)                                                                     7--40 days                                           GDS                                                          No Depression = 5059.6 ± 53.7 steps/day\                   Coehns = 0.03\                                             7
  \[[@B50-ijerph-17-03738]\]                                                                                                                                                       M, F                              (M = 1491, F = 1563)                                                                                                                                                                                                                                                                       Depressed = 5003.0 ± 112.1 steps/day                       *p* = 0.359                                                

  Kangasniemi, 2014\            Finland                                       Adults, general population                                               2011                        Mean 43 ± 5.2 y,                  108 (58 F, 50 M)             *n*.a.                       109               ActiGraph-GT1M, accelerometer LLC, Pensacola, Florida                                        7 days                                               BDI- II                                                      Less Active: 24.3 ± 12.4 min/day\                          r = −0.24, (95% CI 0.38, 0.08)                             7
  \[[@B51-ijerph-17-03738]\]                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    More active: 62.7 ± 24.7 min/day                                                                                      

  King, 2014\                   USA                                           Adults with ≥class 2 obesity.                                            2009                        Mean 45 (18--78) y                850 (673 F, 177 M)           31.8%                        3626              StepWatch™ 3 Activity Monitor (OrthoCare Innovations, Washington, D.C.)                      7 days                                               BDI- II                                                      PA ≥ 1000 steps/day\                                       OR = 1.03 (95% CI 0.97--1.09)c                             7
  \[[@B52-ijerph-17-03738]\]                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    Mean: 7321.0 steps/day                                                                                                

  Loprinzi, 2012\               USA                                           non-institutionalized U.S. civilians                                     2005--2006                  48.4 ± 0.8 y                      1146 (611 M)                 9.5%                         *n*.a.            ActiGraph AM-7164, accelerometer Walton, Beach, FL.                                          7 days                                               PHQ-9                                                        MVPA = 2020--5998 steps/min                                M: OR 0.71 (95% CI 0.53--0.95)\                            10
  \[[@B54-ijerph-17-03738]\]                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                               F:OR = 0.74 (95% CI 0.57--0.96)                            

  Loprinzi 2013 (A)\            USA                                           non-institutionalized USA civilians                                      2006                        Mean: 73.5 ± 0.2 y                708 (57.2% M)                14.9%                        *n*.a.            ActiGraph AM-7164, accelerometer Walton, Beach, FL.                                          7 days                                               PHQ-9                                                        MVPA = 10.0 ± 0.9 min/day                                  OR = 0.78 (95% CI 0.64--0.94)                              9
  \[[@B55-ijerph-17-03738]\]                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          

  Loprinzi, 2013 (B)\           USA                                           Diabetic non-institutionalized USA civilians                             2006                        Mean: 59.6 ± 1.2 y                372 (51.4% F)                3.1%                         *n*.a.            ActiGraph AM-7164, accelerometer Walton, Beach, FL.                                          7 days                                               PHQ-9                                                        MVPA = 12.2 ± 1.3 min/day                                  β = −0.03 (95% CI −0.05---−0.006)\                         10
  \[[@B56-ijerph-17-03738]\]                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                               *p* \< 0.05                                                

  Ludwig, 2018\                 UK                                            UK residents                                                             2013--2015                  69 ± 4.1 y                        1720 (M = 85.5%)             4%                           20                ActiGraph GT3X accelerometer (ActiGraph, Florida, USA)                                       7 days                                               PHQ-9                                                        PA = 6151 steps/day                                        β = −0.170\                                                7
  \[[@B57-ijerph-17-03738]\]                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                               *p* \< 0.001                                               

  Park, 2017\                   UK                                            Subjects living facilities across England                                *n*.a.                      77.5 ± 8.2 y                      85 (M = 31.8%)               *n*.a.                       0                 GT3X+, WGT3X-BT; ActiGraph, Pensacola, FL, USA                                               *n*.a.                                               HADS                                                         MVPA = 9.74 min/day                                        Χ^2^ = 8.45\                                               5
  \[[@B60-ijerph-17-03738]\]                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                               *p* = 0.004                                                

  Song, 2011\                   USA                                           community residents older than 20 years                                  2006                        ≥20 y                             4058 (51.32% F)              19.5%                        6290              ActiGraph^®^ AM-7164, accelerometer Walton, Beach, FL.                                       7 days                                               PHQ-9                                                        MPA = 30 min daily and more than 3 days a week             OR = 0.72 (95% CI 0.54--0.97)\                             7
  \[[@B64-ijerph-17-03738]\]                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                               *p* \< 0.05                                                

  Vallance JK, 2011\            USA                                           non-institutionalized civilian US citizens                               2005--2006                  45.7 ± 13.7 y                     2862 (1417 M)                195                          *n*.a.            ActiGraph AM-7164, accelerometer Walton, Beach, FL.                                          7 days                                               PHQ-9                                                        MVPA = 20.2 ± 0.2 min/day                                  OR = 0.37, (95% CI, 0.20 to 0.70)\                         9
  \[[@B66-ijerph-17-03738]\]                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                               *p* \< 0.01                                                

  Vallance J.K, 2015\           Canada                                        Colon cancer survivors                                                   *n*.a.                      Mean: 64.3 ± 10.3 y M, F          180\                         8.5%                         17                Actigraph GT3X+ accelerometer                                                                7 days                                               PHQ-9                                                        non-extrapolatable                                         non-extrapolatable                                         8
  \[[@B67-ijerph-17-03738]\]                                                                                                                                                                                         (M = 99, F = 81)                                                                                                                                                                                                                                                                                                                                                                                                 

  Whitaker, 2014\               USA                                           Overweight and obese women                                               *n*.a.                      Mean: 38.3 ± 7.6 y                196 (F)                      *n*.a.                       34                ActiGraph-GT1M, accelerometer LLC, Pensacola, Florida                                        7 days                                               CESD-10                                                      MVPA ≥ 2400 steps/min                                      t = 0.30\                                                  9
  \[[@B69-ijerph-17-03738]\]                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                               *p* = 0.77                                                 

  **Case-control studies**                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                            

  O'Brien JT, 2016\             UK                                            adults \> 60yo                                                           2015                        74 ± 6 y                          58 (43 F)                    29                           0                 Accelerometer                                                                                7 days                                               Montgomery--Åsberg Depression Rating Scale (MADRS); GDS-15   0.17 acceleration/min/day                                  r = −0.37\                                                 7
  \[[@B59-ijerph-17-03738]\]                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                               *p* ≤ 0.05                                                 

  **Cohort studies**                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  

  Duenas-Espin, 2016\           Europe (Athens, Leuven, London, Groningen).   COPD patients                                                            July--November 2011         M, F\                             220 (149 M, 71 F)            5%                           *n*.a.            Accelerometer Dynaport MoveMonitor (McRoberts BV, The Hague, the Netherlands).               7 days at baseline, 6 and 12 months                  HADS hospital anxiety and depression scale)\                 4812 ± 3147 steps/day                                      β = 0.6 (95% CI 0.5 to 0.8)\                               5
  \[[@B40-ijerph-17-03738]\]                                                                                                                                                       Mean: 67 ± 8y                                                                                                                                                                                                                                                   (depression\>11 points)                                                                                                 *p* = 0.01                                                 

  **Follow-up** = 1 y                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 

  Po-Wen, 2017\                 Taiwan                                        community-dwelling older adults                                          2012--2014                  Mean: 74.5 y\                     285\                         *n*.a.                       11                ActiGraph GT3X-BT (ActiGraph, Pensacola, FL)                                                 7 day at baseline                                    15-item Geriatric Depression Scale                           MVPA\>1951 steps/min                                       RR: 0.88 95% CI (0.79--0.98)\                              8
  \[[@B53-ijerph-17-03738]\]                                                                                                                                                       M, F                              (M = 125, F = 149)                                                                                                                                                                                                                                                                                                                                    *p* = 0.021                                                

  **Follow-up** = 2 y                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 

  Raudsepp, 2017\               Estonia                                       generally healthy community-dwelling individuals aged 67--74 years       2011--2013                  67--74 y\                         195 (M = 85, F = 110)        *n*.a.                       23                Yamax-Digiwalker pedometer (SW-200-024)                                                      1 week each year, per 3 years                        15-Item Geriatric Depression Scale                           6394.5 daily walking steps                                 β = −0.17\                                                 6
  \[[@B61-ijerph-17-03738]\]                                                                                                                                                       M, F                                                                                                                                                                                                                                                                                                                                                                                    Χ2 = 83.27                                                 

  **Follow-up** = 3 y                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 

  Rethorst, 2017\               USA                                           Hispanic/Latino men and women, age 18 to 74 years at time                2008--2011                  Mean: 41.06 ± 0.25 y\             16,415 (52.13% F)            *n*.a.                       *n*.a.            Actical B-1 version accelerometer                                                            7 days at baseline                                   Center for Epidemiological Studies Depression Scale 10       VPA≥3962 steps/min                                         β = −0.936                                                 4
  \[[@B62-ijerph-17-03738]\]                                                                                                                                                       M, F                                                                                                                                                                                                                                                                                                                                                                                                                                               

  **Follow-up** = 7 days                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              

  Sylvester, 2017\              Canada                                        Breast cancer women over 1 year post-treatment                           *n*.a.                      55.01 ± 10.96 y                   201 F                        *n*.a.                       0                 ActiGraph GT3X-BT (ActiGraph, Pensacola, FL)                                                 7 days every 3 months                                10-item Center for Epidemiologic Studies Depression Scale    MPA = 14.73 ± 11.6 min/day                                 β = −0.73; *p* = 0.03                                      8
  \[[@B64-ijerph-17-03738]\]                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          

  **Follow-up** = 1 y                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 

  Trinh, 2015\                  Canada                                        Patients with breast cancer in stage I--III without metastatic disease   2010--2012                  Mean: 55 ± 11 y\                  199 (F)                      *n*.a.                       4                 ActiGraph GT3X-BT (ActiGraph, Pensacola, FL)                                                 7 days at baseline                                   CES-D10                                                      MVPA mean 107.1 ± 81.3 min/week)                           β = −0.10\                                                 4
  \[[@B65-ijerph-17-03738]\]                                                                                                                                                       F                                                                                                                                                                                                                                                                                                                                                                                       *p* = 0.19                                                 

  **Follow-up** = 7 days                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              

  **Trial studies**                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                   

  **Author**\                   **Country**                                   **Characteristics**                                                      **Study Period**            **Age and Gender**                **Sample Size**              **Depressed Subjects**       **Attrition +**   **Device Used**                                                                              **Duration of Measurement**                          **Tool Used for Depression Diagnosis**                       **PA**                                                     **Results**                                                **Follow-up**
  **Year**                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                            

  Abedi, 2015\                  Iran                                          Post-menopausal women                                                    *n*.a.                      *n*.a.                            106 F                        *n*.a.                       *n*.a.            Pedometer                                                                                    12 weeks                                             BDI-II                                                       Before 76,377 steps/months; after: 106398/month            Intervention vs. control group 13.7 ± 5 vs. 19.6 ± 4.79\   12 weeks
  \[[@B30-ijerph-17-03738]\]                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                               *p* \< 0.001                                               

  Freitas, 2018\                Brazil                                        Obese adults with asthma                                                 *n*.a.                      30--60 y                          51 F                         58.8%                        *n*.a             ActiGraph GT3X-BT (ActiGraph, Pensacola, FL)                                                 7 days                                               HADS                                                         Training group (after): 10,000 steps/day\                  r = 0.52\                                                  3 months
  \[[@B43-ijerph-17-03738]\]                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    Control group(after): \~8000 steps/day                     *p* \< 0.01                                                

  Golsteijn, 2018\              Holland                                       prostate and colorectal cancer patients survivors                        2015--2016                  66.5 ± 7.1 y                      427 (M, F)                   *n*.a.                       na                ActiGraph GT3X-BT (ActiGraph, Pensacola, FL)                                                 7 days                                               HADS                                                         MVPA \> 3 MET\                                             β = −0.64\                                                 6 months
  \[[@B45-ijerph-17-03738]\]                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    MVPA = 271 ± 211 min/week                                  *p* = 0.005                                                

  Hallam, 2018\                 India, Australia, and 21 other countries      General Population, of Stepathlon corporate challenge                    2015/16                     16--74 y                          1963 (1458 M, 505 F)         *n*.a.                       na                own personal pedometer, or activity monitoring device                                        100 days                                             DASS                                                         *n*.a.                                                     r = − 0.026\                                               100 days
  \[[@B46-ijerph-17-03738]\]                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                               *p*  = 0.254                                               

  Hartescu I, 2015\             UK                                            Inactive people with insomnia                                            2014                        59.8 ± 9.46 yo                    41 (30 F, 11 M)              *n*.a.                       *n*.a.            ActiGraph GT3X-BT (ActiGraph, Pensacola, FL)                                                 6 months                                             BDI-II                                                       Intervention group 66.50 ± 30.37\                          Cohen: 0.87 (0.19--1.56)                                   6 months
  \[[@B47-ijerph-17-03738]\]                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    (min per week)                                                                                                        

  Hospes G, 2009\               Netherlands                                   COPD patients                                                            2008                        63.1 ± 8.3 y                      35 (21 M)                    *n*.a.                       *n*.a.            Pedometer Digiwalker SW-2000 (Yamax; Tokyo, Japan)                                           12 weeks                                             BDI-II                                                       Intervention group\                                        β = 0.93\                                                  12 weeks
  \[[@B48-ijerph-17-03738]\]                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    Before 7087 ± 4058\                                        *p* = 0.01                                                 
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                After\                                                                                                                
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                7872 ± 3962                                                                                                           

  van den Berg-Emons, 2004\     Netherlands                                   Patients with stable chronic heart failure                               *n*.a.                      58.6 ± 12.1                       34 (25 M e 9 F)              *n*.a.                       *n*.a.            Accelerometer (AM, Temec Instruments, Kerkrade                                               48 h                                                 HADS                                                         Intervention group: 9.9% (of 24 h)\                        Intervention group: 3.4(±4.0);\                            3 months
  \[[@B68-ijerph-17-03738]\]                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    Control group: 7.4%                                        Control group: 4.8 ± (3.1)                                 

  Vetrovsky T, 2017\            Czech Republic                                inactive people from general population in primary care setting          2015                        41 ± 10 y                         23 (12 M, 11 F)              0 at baseline                0                 tri- axial pedometer (eVito 3D Step Counter SL; HMM Diagnostics GmbH, Dossenheim, Germany)   7 days                                               HADS                                                         After = +1676                                              Mean difference = −2.4 \[95% CI −3.7, −1.2\]\              3 months
  \[[@B70-ijerph-17-03738]\]                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                               *p* = 0.001                                                
  ---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

\+ Number of subjects lost or incomplete data; *n*.a. not available; *n*.s. not specified; QS = quality score; COPD Chronic obstructive pulmonary disease; UK United Kingdom; USA United States of America; MVPA moderate-to-vigorous physical activity; M male; F female; BDI-II Beck Depression Inventory-II; HADS Hospital Anxiety and Depression Scale; GDS Goldberg Depression Scale; Center for Epidemiologic Studies for Depression Scale CESD-10; PHQ-9 Patient Health Questionnaire-9; DASS-21 Depression Anxiety Stress Scales.
